March 2019

Anticancer Antibody Receives First Funds for Trial in Leukemia Patients

Chart of data showing that Allterum reduces leukemia cells in samples to almost zero

An anti-leukemia compound identified at NCI at Frederick is one step closer to entering clinical trials in humans thanks to a $4.2-million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). CPRIT recently gave the funds to Allterum Therapeutics, Inc., a Texas-based biotechnology startup company created to manufacture the compound, Allterum, and advance it to human trials. The grant represents the first step in the multi-million-dollar process to bring Allterum to the clinic.



Subscribe to March 2019